Citigroup’s BridgeBio Pharma BBIO Stock Holding History

Citigroup’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.34M	Sell	45,000 -3,500	-7%	-$254K	﹤0.01%	2283
2025 Q4	$3.71M	Hold	48,500	–	–	﹤0.01%	2229
2025 Q3	$2.52M	Sell	48,500 -72,500	-60%	-$3.54M	﹤0.01%	2482
2025 Q2	$5.22M	Sell	121,000 -94,400	-44%	-$3.43M	﹤0.01%	1856
2025 Q1	$7.45M	Buy	215,400 +51,400	+31%	+$1.73M	﹤0.01%	1587
2024 Q4	$4.5M	Buy	164,000 +137,000	+507%	+$3.54M	﹤0.01%	2077
2024 Q3	$687K	Hold	27,000	–	–	﹤0.01%	3527
2024 Q2	$684K	Sell	27,000 -39,900	-60%	-$1.09M	﹤0.01%	3184
2024 Q1	$2.07M	Buy	66,900 +10,000	+18%	+$340K	﹤0.01%	2411
2023 Q4	$2.3M	Buy	56,900 +28,500	+100%	+$856K	﹤0.01%	2126
2023 Q3	$749K	Buy	28,400 +5,700	+25%	+$162K	﹤0.01%	2747
2023 Q2	$390K	Hold	22,700	–	–	﹤0.01%	3540
2023 Q1	$376K	Buy	+22,700	New	+$265K	﹤0.01%	3325
2022 Q4	–	Sell	-39,100	Closed	-$389K	–	5773
2022 Q3	$389K	Buy	+39,100	New	+$406K	﹤0.01%	3414

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's BBIO Position: Q1 2026 in Review

Citigroup increased its BridgeBio Pharma (BBIO) stake by 6.6% in Q1 2026, buying an estimated $3.35M and bringing the position to 746,483 shares worth $55.4M. The position accounts for 0.02% of the portfolio, ranked #602.

Citigroup first reported a position in BBIO in Q3 2019 and has held it in 27 quarters since. The position peaked at $62.9M in Q4 2023. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Citigroup held 746,483 shares of BridgeBio Pharma worth $55.4M as of Q1 2026.
Citigroup bought 46,232 BridgeBio Pharma shares in Q1 2026, an estimated $3.35M.
BridgeBio Pharma made up 0.02% of Citigroup's portfolio in Q1 2026, its #602 holding.
Citigroup first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 27 quarters since.
Citigroup's BridgeBio Pharma position peaked at $62.9M in Q4 2023.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.